Quest Diagnostics, Royalty Pharma deal

Royalty Pharma acquired from diagnostic company Quest Diagnostics the rights to royalties for cancer compound ibrutinib for $485 million in cash. Quest said the deal is

Read the full 269 word article

How to gain access

Continue reading with a
two-week free trial.